{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:46:55Z","timestamp":1793724415265,"version":"4.6.1"},"reference-count":62,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"InFLAMES Flagship Programme of the Academy of Finland","award":["337530, 357910, 358823"],"award-info":[{"award-number":["337530, 357910, 358823"]}]},{"name":"Research Council of Finland grant for clinical researcher","award":["330902"],"award-info":[{"award-number":["330902"]}]},{"name":"National MS Society and the National Stem Cell Foundation"},{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9liuksen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004012","name":"Jane ja Aatos Erkon S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004012","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Neurol Disord"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Multiple sclerosis (MS) manifests clinically as relapsing disease (relapsing-remitting MS (RRMS)), progressive disease, or as combination of these phenotypes. The underlying pathology for relapses and focal inflammatory activity is driven by adaptive immune cells, whereas brain-compartmentalized pathology promoted by innate immune cell activation likely contributes to progression.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>To explore the usability of various imaging and soluble biomarkers in predicting change in clinical phenotype from RRMS to secondary progressive MS (SPMS).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Design:<\/jats:title>\n            <jats:p>Prospective longitudinal study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>\n              Twenty-three RRMS patients aged 40\u201350\u2009years had clinical evaluation, brain MR imaging, serum neurofilament light and glial fibrillary acidic protein (GFAP) measurements, and brain positron emission tomography with translocator protein (TSPO)-binding radioligand [\n              <jats:sup>11<\/jats:sup>\n              C](R)-PK11195 at baseline. Patients were followed for 5\u2009years and assessed for signs of conversion to SPMS at the end of follow-up. Evolution to SPMS was determined based on an increased Expanded Disability Status Score and significant accrual of clinical symptoms.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>After 5\u2009years, 8\/23 (35%) patients had converted to SPMS. At baseline, they had increased TSPO-binding in the normal appearing white matter, thalamus, and perilesional area compared to patients who did not convert to SPMS. The proportion and number of TSPO-rim-active lesions were higher among patients developing SPMS. Higher concentration of GFAP and more pronounced thalamic atrophy were also observed among the SPMS convertors.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>The results suggest that imaging and serum biomarkers reporting on compartmentalized central nervous system inflammation support identification of MS patients at risk of SPMS conversion. Evaluation of thalamic atrophy and measurement of soluble biomarkers can be implemented in the assessment of individual patients\u2019 progression risk in daily clinical practice. This can help in identifying patients who are at greatest need of smoldering pathology-targeting therapy. Larger studies are needed to validate these results.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration:<\/jats:title>\n            <jats:p>\n              NCT3134716 role of microglia in the pathogenesis of progressive multiple sclerosis,\n              <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03134716\">https:\/\/clinicaltrials.gov\/study\/NCT03134716<\/jats:ext-link>\n              .\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1177\/17562864251357276","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T05:52:42Z","timestamp":1757483562000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Predictors of risk of secondary progression in multiple sclerosis"],"prefix":"10.1177","volume":"18","author":[{"given":"Sini","family":"Laaksonen","sequence":"first","affiliation":[{"name":"Turku PET Centre, University of Turku, Kiinamyllynkatu 4\u20138, Turku 20521, Finland"},{"name":"Clinical Neurosciences, University of Turku, Turku, Finland"},{"name":"Neurocenter, Turku University Hospital, Turku, Finland"},{"name":"InFLAMES Research Flagship, University of Turku, Turku, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0432-2931","authenticated-orcid":false,"given":"Marcus","family":"Sucksdorff","sequence":"additional","affiliation":[{"name":"Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland"},{"name":"Clinical Neurosciences, University of Turku, Turku, Finland"},{"name":"Neurocenter, Turku University Hospital, Turku, Finland"},{"name":"InFLAMES Research Flagship, University of Turku, Turku, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Vuorimaa","sequence":"additional","affiliation":[{"name":"Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland"},{"name":"Clinical Neurosciences, University of Turku, Turku, Finland"},{"name":"Neurocenter, Turku University Hospital, Turku, Finland"},{"name":"InFLAMES Research Flagship, University of Turku, Turku, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Kuhle","sequence":"additional","affiliation":[{"name":"Department of Neurology University Hospital and University of Basel, Basel, Switzerland"},{"name":"Departments of Biomedicine and Clinical Research, Multiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), University Hospital and University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6695-5684","authenticated-orcid":false,"given":"Marjo","family":"Nylund","sequence":"additional","affiliation":[{"name":"Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland"},{"name":"Clinical Neurosciences, University of Turku, Turku, Finland"},{"name":"Neurocenter, Turku University Hospital, Turku, Finland"},{"name":"InFLAMES Research Flagship, University of Turku, Turku, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Rajander","sequence":"additional","affiliation":[{"name":"Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland"},{"name":"\u00c5bo Akademi University, Turku, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saara","family":"Wahlroos","sequence":"additional","affiliation":[{"name":"Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Matilainen","sequence":"additional","affiliation":[{"name":"Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland"},{"name":"Clinical Neurosciences, University of Turku, Turku, Finland"},{"name":"Neurocenter, Turku University Hospital, Turku, Finland"},{"name":"InFLAMES Research Flagship, University of Turku, Turku, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maija","family":"Saraste","sequence":"additional","affiliation":[{"name":"Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland"},{"name":"Clinical Neurosciences, University of Turku, Turku, Finland"},{"name":"Neurocenter, Turku University Hospital, Turku, Finland"},{"name":"InFLAMES Research Flagship, University of Turku, Turku, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9751-5881","authenticated-orcid":false,"given":"Laura","family":"Airas","sequence":"additional","affiliation":[{"name":"Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland"},{"name":"Clinical Neurosciences, University of Turku, Turku, Finland"},{"name":"Neurocenter, Turku University Hospital, Turku, Finland"},{"name":"InFLAMES Research Flagship, University of Turku, Turku, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000560"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458512451510"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458507084264"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2010.208173"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24747"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.20588"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211010128"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458519868990"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.03116"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00289-7"},{"key":"e_1_3_4_12_2","article-title":"Toward precision phenotyping of multiple sclerosis","volume":"9","author":"Pitt D","unstructured":"Pitt D, Lo CH, Gauthier SA, et al. Toward precision phenotyping of multiple sclerosis. Neurol Neuroimmunol Neuroinflamm; 9: e200025.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.27034"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26913"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2015-001139"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.33.11.1444"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000443"},{"key":"e_1_3_4_19_2","article-title":"Phenotyping of multiple sclerosis lesions according to innate immune cell activation using 18 kDa translocator protein-PET","volume":"4","author":"Nylund M","unstructured":"Nylund M, Sucksdorff M, Matilainen M, et al. Phenotyping of multiple sclerosis lesions according to innate immune cell activation using 18 kDa translocator protein-PET. Brain Commun; 4: fcab301.","journal-title":"Brain Commun"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/mrm.26946"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15834"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awae013"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.113.131698"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.2010.64"},{"key":"e_1_3_4_25_2","first-page":"158","article-title":"Reference and target region modeling of [11C]-(R)-PK11195 brain studies","volume":"48","author":"Turkheimer FE","year":"2007","unstructured":"Turkheimer FE, Edison P, Pavese N, et al. Reference and target region modeling of [11C]-(R)-PK11195 brain studies. J Nucl Med 2007; 48: 158\u2013167.","journal-title":"J Nucl Med"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.2012.59"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2023-331051"},{"key":"e_1_3_4_28_2","doi-asserted-by":"crossref","unstructured":"Benkert P Meier S Schaedelin S et al. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurol 2022; 21(3): 246\u2013257.","DOI":"10.1016\/S1474-4422(22)00009-6"},{"key":"e_1_3_4_29_2","article-title":"Transition to secondary progressive multiple sclerosis: the consequences for patients and healthcare systems, a healthcare professional survey","volume":"5","author":"Caseby SCL","unstructured":"Caseby SCL, Woodhouse FA, Montgomery SM, et al. Transition to secondary progressive multiple sclerosis: the consequences for patients and healthcare systems, a healthcare professional survey. Health Sci Rep; 5: e474.","journal-title":"Health Sci Rep"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458512463764"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458512445941"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww173"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30475-6"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458518783667"},{"key":"e_1_3_4_35_2","article-title":"Proportion and characteristics of secondary progressive multiple sclerosis in five European registries using objective classifiers","volume":"9","author":"Forsberg L","unstructured":"Forsberg L, Spelman T, Klyve P, et al. Proportion and characteristics of secondary progressive multiple sclerosis in five European registries using objective classifiers. Mult Scler J Exp Transl Clin; 9: 20552173231153557.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106268"},{"key":"e_1_3_4_37_2","article-title":"Slowly expanding lesions predict 9-year multiple sclerosis disease progression","volume":"9","author":"Preziosa P","unstructured":"Preziosa P, Pagani E, Meani A, et al. Slowly expanding lesions predict 9-year multiple sclerosis disease progression. Neurol Neuroimmunol Neuroinflamm; 9: e1139.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.52187"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585221114750"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awad218"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011494"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25145"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25150"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.5250"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.2137"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103590"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa275"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.231340"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001182"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26657"},{"key":"e_1_3_4_51_2","article-title":"TSPO-detectable chronic active lesions predict disease progression in multiple sclerosis","volume":"10","author":"Polvinen E","unstructured":"Polvinen E, Matilainen M, Nylund M, et al. TSPO-detectable chronic active lesions predict disease progression in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm; 10: e200133.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.2399"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585241229956"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-021-00537-1"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.104970"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.27096"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.100978"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00095-8"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.106148"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003542"},{"key":"e_1_3_4_61_2","article-title":"Natalizumab treatment reduces microglial activation in the white matter of the MS brain","volume":"6","author":"Sucksdorff M","unstructured":"Sucksdorff M, Tuisku J, Matilainen M, et al. Natalizumab treatment reduces microglial activation in the white matter of the MS brain. Neurol Neuroimmunol Neuroinflamm; 6: e574.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa436"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2415988"}],"container-title":["Therapeutic Advances in Neurological Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864251357276","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562864251357276","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864251357276","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T13:18:40Z","timestamp":1757942320000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562864251357276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":62,"alternative-id":["10.1177\/17562864251357276"],"URL":"https:\/\/doi.org\/10.1177\/17562864251357276","relation":{},"ISSN":["1756-2864","1756-2864"],"issn-type":[{"value":"1756-2864","type":"print"},{"value":"1756-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"article-number":"17562864251357276"}}